CRISPR Therapeutics, Casgevy Potential

This is a news story, published by Yahoo Finance, that relates primarily to Amtagvi news.

Amtagvi news

For more Amtagvi news, you can click here:

more Amtagvi news

drug discoveries news

For more drug discoveries news, you can click here:

more drug discoveries news

Yahoo Finance news

For more news from Yahoo Finance, you can click here:

more news from Yahoo Finance

About the Otherweb

Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about

CRISPR Therapeutics

. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest gene therapy news, CRISPR news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!

powerful gene editing therapies

The Motley Fool

•

2 Top Biotech Stocks to Buy Now and Hold For 5 Years or More

Summary

Nutrition label

77% Informative

CRISPR Therapeutics has a bunch of gene therapy and gene editing programs in clinical trials.

Iovance Biotherapeutics is rolling out its first treatment, a cell therapy called Amtagvi .

With revenue of $58.6 million in the third quarter , it expects sales of $165 million in 2024 and as much as $475 million in 2025 .

The Stock Advisor service has more than quadrupled the return of S&P 500 since 2002

Stock Advisor returns as of November 11, 2024 Alex Carchidi has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends CRISPR Therapeutics , Iovance Biotherapeutics , and Vertex Pharmaceuticals . The Motley Fool has a disclosure policy. 2 Top Biotech Stocks to Buy Now and Hold For 5 Years or More was originally published by The Motley Fool .